PT2257309T - Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos - Google Patents

Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos

Info

Publication number
PT2257309T
PT2257309T PT97141915T PT09714191T PT2257309T PT 2257309 T PT2257309 T PT 2257309T PT 97141915 T PT97141915 T PT 97141915T PT 09714191 T PT09714191 T PT 09714191T PT 2257309 T PT2257309 T PT 2257309T
Authority
PT
Portugal
Prior art keywords
bacterio
rgd
chlorophyll
conjugates
tumors
Prior art date
Application number
PT97141915T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Yeda Res And Development Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res And Development Company Ltd filed Critical Yeda Res And Development Company Ltd
Publication of PT2257309T publication Critical patent/PT2257309T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0451—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
PT97141915T 2008-02-27 2009-03-01 Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos PT2257309T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6429808P 2008-02-27 2008-02-27

Publications (1)

Publication Number Publication Date
PT2257309T true PT2257309T (pt) 2020-01-22

Family

ID=40677556

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97141915T PT2257309T (pt) 2008-02-27 2009-03-01 Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos

Country Status (15)

Country Link
US (1) US8815213B2 (cg-RX-API-DMAC7.html)
EP (2) EP2257309B1 (cg-RX-API-DMAC7.html)
JP (1) JP5620279B2 (cg-RX-API-DMAC7.html)
KR (1) KR101595138B1 (cg-RX-API-DMAC7.html)
CN (1) CN102036684B (cg-RX-API-DMAC7.html)
AU (1) AU2009219682B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0907791A2 (cg-RX-API-DMAC7.html)
CA (1) CA2717060C (cg-RX-API-DMAC7.html)
DK (1) DK2257309T3 (cg-RX-API-DMAC7.html)
ES (1) ES2764781T3 (cg-RX-API-DMAC7.html)
MX (1) MX2010009530A (cg-RX-API-DMAC7.html)
PT (1) PT2257309T (cg-RX-API-DMAC7.html)
RU (1) RU2518296C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009107139A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201006789B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1968648T3 (en) 2005-12-16 2015-07-27 Amit Shachaf Diagnostic system for the detection and diagnosis of skin cancer
US9957293B2 (en) * 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2011020107A2 (en) * 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
KR101253709B1 (ko) * 2011-06-02 2013-04-12 경북대학교 산학협력단 분비형 표적 추적 융합 단백질
EP2774625B1 (en) * 2011-09-05 2017-04-12 Hiroshi Maeda Polymer-type fluorescent molecule probe
US9798856B2 (en) * 2012-03-21 2017-10-24 Koninklijke Philips N.V. Clinical workstation integrating medical imaging and biopsy data and methods using same
CN103705532B (zh) * 2012-10-08 2016-09-14 浙江海正药业股份有限公司 靶向胸苷激酶光敏剂及其药物组合物与治疗癌症的用途
EP3148583B1 (en) 2014-06-02 2020-04-29 Li-Cor, Inc. Phthalocyanine probes and uses thereof
CA2954463C (en) 2014-08-08 2023-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
CA2969251C (en) * 2014-12-08 2023-08-15 Arash Zarrine-Afsar System and method for enhanced mass spectrometry imaging
JP6793122B2 (ja) * 2014-12-19 2020-12-02 ブラッコ・イメージング・ソシエタ・ペル・アチオニBracco Imaging S.P.A. 術中イメージング
PL3166606T3 (pl) * 2015-06-03 2018-10-31 Surgimab S.A.S. Koniugaty fluorescencyjne
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
WO2017049403A1 (en) 2015-09-22 2017-03-30 University Health Network System and method for optimized mass spectrometry analysis
EP3559018A1 (en) * 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
MX2019007367A (es) * 2016-12-23 2020-01-27 Bicycletx Ltd Ligandos de peptido para enlace a mt1-mmp.
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
EP3664892A4 (en) 2017-08-08 2021-04-28 Board of Trustees of Michigan State University TUNED LUMINESCENT ORGANIC SALT FOR ENHANCED IMAGING AND PHOTODYNAMIC THERAPY
JP6920931B2 (ja) * 2017-09-01 2021-08-18 富士フイルム株式会社 医療画像処理装置、内視鏡装置、診断支援装置、及び、医療業務支援装置
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
RU2700407C1 (ru) * 2018-07-23 2019-09-16 Михаил Тимофеевич Александров Способ лечения опухолевых и воспалительных заболеваний с применением фотодинамической терапии
CN111171030B (zh) * 2018-11-12 2022-11-22 浙江海正药业股份有限公司 细菌叶绿素衍生物及其制备方法
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP7744340B2 (ja) * 2019-12-05 2025-09-25 テンパス・エーアイ・インコーポレイテッド ハイスループット薬物スクリーニングのためのシステムおよび方法
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
AU2021416188A1 (en) 2020-12-31 2023-07-06 Orlucent, Inc. Systems and methods for assessing tissue remodeling
CN112933252A (zh) * 2021-01-28 2021-06-11 厦门大学附属翔安医院 一种乳腺癌特异靶向分子探针及其制备方法和应用
CN115466311A (zh) * 2021-06-10 2022-12-13 首都医科大学 抗粘附迁移和侵袭的18β-甘草次酸-RGDK,其合成,抗癌转移活性和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121876A1 (de) 1991-07-02 1993-01-14 Scheer Hugo Modifizierte bakteriochlorophylle, verfahren zu ihrer herstellung und ihre verwendung
JPH07503944A (ja) 1991-11-22 1995-04-27 イエダ リサーチ アンド デベロツプメント カンパニー リミテツド Arg−gly−asp配列の非ペプチド代替物およびそれらからなる医薬組成物
IL102645A (en) * 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US6147195A (en) 1993-07-26 2000-11-14 Yeda Research And Development Co., Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
IL116126A0 (en) 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
WO1998010795A2 (en) 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
DE19756773A1 (de) * 1997-12-19 1999-06-24 Dade Behring Marburg Gmbh Neues Verfahren und Diagnosemittel zur Hämostase-Diagnostik
PL201172B1 (pl) 1998-12-09 2009-03-31 Yeda Res & Dev Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
US7045117B2 (en) 1999-12-01 2006-05-16 Yeda Research And Development Co. Ltd. Method for tumor diagnosis comprising administering of palladium-substituted bacteriochlorophyll derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
EP1753457B8 (en) 2004-06-07 2016-09-21 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
US20070258908A1 (en) * 2006-04-27 2007-11-08 Lanza Gregory M Detection and imaging of target tissue
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
US20110223102A1 (en) * 2007-09-14 2011-09-15 Health Research, Inc. Multimodality agents for tumor imaging and therapy

Also Published As

Publication number Publication date
EP2712627A3 (en) 2014-04-16
BRPI0907791A2 (pt) 2015-08-04
AU2009219682B2 (en) 2015-06-18
KR20100127798A (ko) 2010-12-06
JP2011513298A (ja) 2011-04-28
EP2257309B1 (en) 2019-10-16
JP5620279B2 (ja) 2014-11-05
RU2010139461A (ru) 2012-04-10
CA2717060C (en) 2016-11-01
EP2712627A2 (en) 2014-04-02
CN102036684A (zh) 2011-04-27
MX2010009530A (es) 2010-11-30
US20110064658A1 (en) 2011-03-17
AU2009219682A1 (en) 2009-09-03
ZA201006789B (en) 2012-01-25
US8815213B2 (en) 2014-08-26
WO2009107139A1 (en) 2009-09-03
EP2257309A1 (en) 2010-12-08
ES2764781T3 (es) 2020-06-04
RU2518296C2 (ru) 2014-06-10
CN102036684B (zh) 2017-06-09
CA2717060A1 (en) 2009-09-03
KR101595138B1 (ko) 2016-02-18
DK2257309T3 (da) 2020-01-20

Similar Documents

Publication Publication Date Title
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0907791A2 (pt) Conjugados rgd-(bacterio)clorofila para terapia fotodinâmica e formação de imagem de tumores necróticos
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI0822560A2 (pt) Instrumento para aplicações endoscópicas ou semelhantes
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
DK2121139T3 (da) Formulations for cancer treatment
BRPI1016234A2 (pt) dispositivo aplicador para uso médico e/ou cosmético.
BRPI0919979A2 (pt) formulações de moléculas de ligação de antígeno de domínio único
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI0812753A2 (pt) Combinações de substância ativas acaricidas
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BRPI0906444A2 (pt) Compostos de 4-piridinona e seu uso para câncer
IL220386B (en) Compositions for the liquidation of tumors and uses thereof
BRPI0912683A2 (pt) tratamento de tumores metastáticos
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
EP2283862A4 (en) CANCER AGENT
BRPI0914683A2 (pt) dispositivo para terapia de campo magnético
LT3011975T (lt) Kietoji kompozicija, skirta dažiklio vartojimui per burną ir jos diagnostinis panaudojimas
BRPI0922884A2 (pt) compostos para tratamento de câncer
EP2340851A4 (en) DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
HUE036490T2 (hu) Tumorok kezelése anti-L1 antitest alkalmazásával
BRPI0921935A2 (pt) composições adesivas de uso médico
SI2340271T1 (sl) Konjugati polimer-bioaktivnega sredstva